Understanding the Current Rating
The 'Sell' rating assigned to Astrazeneca Pharma India Ltd indicates a cautious stance for investors considering this stock. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the stock’s attractiveness and risk profile in the current market environment.
Quality Assessment
As of 19 June 2026, Astrazeneca Pharma India Ltd maintains a good quality grade. This reflects the company’s solid operational foundation and consistent profitability metrics. The return on equity (ROE) stands at a robust 24%, signalling efficient use of shareholder capital. Despite this, the company’s operating profit growth over the last five years has been moderate, averaging an annual rate of 15.14%, which is considered poor relative to high-growth peers in the pharmaceuticals sector. This suggests that while the company is fundamentally sound, its growth trajectory is somewhat subdued.
Valuation Considerations
The stock is currently rated very expensive on valuation grounds. Astrazeneca Pharma India Ltd trades at a price-to-book (P/B) ratio of 26.6, which is significantly higher than the historical averages of its peer group. This premium valuation implies that the market has high expectations for future growth and profitability. However, the latest data shows that profits have declined by 5.3% over the past year, raising concerns about whether the current price adequately reflects the company’s financial realities. Investors should be wary of paying a premium for a stock whose earnings are under pressure.
Financial Trend Analysis
The financial trend for Astrazeneca Pharma India Ltd is currently flat. The company reported flat results in the quarter ending March 2026, with profit before tax (PBT) less other income at ₹53.27 crores, down 12.6% compared to the previous four-quarter average. Similarly, profit after tax (PAT) for the quarter was ₹45.71 crores, a decline of 12.2% versus the prior four-quarter average. These figures indicate a lack of momentum in earnings growth, which is a critical factor for investors seeking capital appreciation. The flat financial trend, combined with a high valuation, contributes to the cautious rating.
Technical Outlook
From a technical perspective, the stock is rated as mildly bearish. Recent price movements show a mixed performance: a 1-day decline of 1.00%, a 1-week gain of 2.25%, but a 1-month drop of 2.98%. Over the last six months, the stock has fallen by 6.99%, and year-to-date returns stand at -6.45%. The one-year return is negative at -10.55%, underperforming the broader BSE500 index, which has generated a positive return of 1.03% over the same period. This underperformance relative to the market highlights the stock’s current weakness in price momentum and investor sentiment.
Market Performance and Investor Implications
As of 19 June 2026, Astrazeneca Pharma India Ltd’s stock performance has been disappointing for investors. The negative returns over the past year, coupled with declining profits and a high valuation, suggest limited upside potential in the near term. The 'Sell' rating reflects these concerns, signalling that investors may want to consider reducing exposure or avoiding new positions until there is clearer evidence of financial improvement or a more attractive valuation.
Sector Context
Within the Pharmaceuticals & Biotechnology sector, Astrazeneca Pharma India Ltd’s valuation stands out as particularly stretched. While the sector often commands premium multiples due to growth prospects and innovation potential, the company’s flat financial trend and profit declines contrast with the more positive trajectories seen in some peers. This divergence further justifies the cautious stance on the stock.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
What the Mojo Score Indicates
The MarketsMOJO score for Astrazeneca Pharma India Ltd currently stands at 42.0, categorised as a 'Sell' grade. This score reflects the combined impact of the company’s quality, valuation, financial trend, and technical outlook. The score has declined by 12 points from 54, the previous 'Hold' rating level, as of the rating update on 02 Jan 2026. This quantitative assessment supports the qualitative analysis, reinforcing the recommendation for investors to exercise caution.
Summary for Investors
In summary, Astrazeneca Pharma India Ltd’s current 'Sell' rating by MarketsMOJO is grounded in a thorough evaluation of its financial health and market performance as of 19 June 2026. While the company maintains good quality metrics, its very expensive valuation, flat financial trend, and mildly bearish technical signals suggest limited near-term upside. Investors should carefully weigh these factors against their portfolio objectives and risk tolerance before considering exposure to this stock.
Looking Ahead
For Astrazeneca Pharma India Ltd to warrant a more favourable rating, improvements in earnings growth and a more reasonable valuation would be necessary. Monitoring quarterly results for signs of profit recovery and tracking sector developments will be key for investors seeking to reassess the stock’s potential in the coming months.
Final Note
It is important to remember that the rating was last updated on 02 Jan 2026, but all financial data and returns discussed here are current as of 19 June 2026. This ensures that investors have the most relevant information to make informed decisions in today’s market environment.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
